drugset / Trial / NCT05234580

Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis

NCT05234580

Phase 2 Completed 204 enrolled Anhui Palo Alto Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Nasal Spray in patients with seasonal allergic rhinitis.

Timeline

Start
2022-04-15
Primary completion
2022-10-10
Completion
2022-12-25

Drugs

EvaluationDrugModalityDoseRoute
Subject PA9159 Small molecule 10 ug Intranasal
Subject PA9159 Small molecule 20 ug Intranasal
Subject PA9159 Small molecule 40 ug Intranasal

Indications